The coronavirus disease 2019 (COVID-19) has continued to spread worldwide since late
2019. To expedite the process of providing treatment to those who have contracted the …

Background Repurposing is a drug development strategy receiving heightened attention
after the Food and Drug Administration granted emergency use authorization of several …

Abstract Coronavirus disease 2019 (COVID-19) is caused by a novel virus named Severe
Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). This virus induced a large …

The COVID-19 pandemic caused by SARS-CoV-2 is an unprecedentedly significant health
threat, prompting the need for rapidly developing antiviral drugs for the treatment. Drug …

Background COVID-19 is an illness caused by severe acute respiratory syndrome
coronavirus 2. Due to its rapid spread, in March 2020 the World Health Organization (WHO) …

Drug repurposing is of interest for therapeutics innovation in many human diseases
including coronavirus disease 2019 (COVID-19). Methodological innovations in drug …

The coronavirus disease 2019 (COVID-19) world health emergency is calling scientists for
unprecedented, huge investigation efforts to urgently answer key questions: what is the …

Currently, there are about 7000 identified rare diseases, together affecting 10% of the
population. However, fewer than 6% of all rare diseases have an approved treatment option …

The newly emerged 2019 novel coronavirus (CoV), named as severe acute respiratory
syndrome CoV-2 (SARS-CoV-2), like SARS-CoV (now, SARS-CoV-1) and Middle East …

Drug repurposing is at the heart of precision oncology. The move from tissue-or cancer-
specific treatments to genomic-or actionable-target treatments necessarily entails the reuse …